Full Press Release Details
INDIANAPOLIS , March 24, 2020 /PRNewswire/ -- To keep the diabetes community informed about important developments from the COVID-19 crisis, Eli Lilly and Company (NYSE: LLY ) today is providing updates related to insulin supply and affordability:
"COVID-19 is an unprecedented challenge for all of us, but Lilly has planned for such events," said Mike Mason , president, Lilly Diabetes. "Our manufacturing facilities, supply chain, and Lilly Diabetes Solution Center are designed to support those who rely on insulin. We are committed to providing a regular supply of safe insulin, and our Solution Center can provide real insulin affordability assistance for people during this difficult time, including people whose jobs have gone away. If you need help, please call the Lilly Diabetes Solution Center."
About Diabetes Approximately 34 million Americans 1 (just over 1 in 10) and an estimated 463 million adults worldwide 2 have diabetes. Type 2 diabetes is the most common type internationally, accounting for an estimated 90 to 95 percent of all diabetes cases in the United States alone 1 . Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin.
About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom . P-LLY
This release contains forward-looking statements regarding product supply, assistance for people living with diabetes, and COVID-19. These statements are based on management's current expectations, but actual results may differ materially. Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
1 Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA : Centers for Disease Control and Prevention, U.S. Dept. of Health and Human Services; 2020.
2 International Diabetes Federation. IDF Diabetes Atlas, 9 th edn. Brussels, Belgium : International Diabetes Federation, 2019. Available at: http://diabetesatlas.org .
Refer to: Greg Kueterman [email protected] ; 317-432-5195 (Lilly Diabetes) Kevin Hern ; [email protected] ; 317-277-1838 (Investors)
SOURCE Eli Lilly and Company